{'fraction_non_alphanumeric': 0.027303754266211604, 'fraction_numerical': 0.028156996587030716, 'mean_word_length': 4.260089686098655, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Studies on the terminal stages of immune hemolysis. V. Evidence that not all complement-produced transmembrane channels are equal.

The inhibitory effects of 0.1 M EDTA on the lysis of E prepared by incubating EA with whole GPC was studied. At high end point lysis (greater than 70%) 0.1 M EDTA failed to prevent hemoglobin release whereas at lower end point (less than 60%) 0.1 M EDTA was effective. In all cases hemoglobin release was inhibited by 25% BSA. When E were prepared by incubating EAC1-8 with C9, similar results were obtained. In this system the difference in the ability of 0.1 M EDTA to inhibit hemoglobin release at high or low end point lysis could not be correlated with the low end point lysis could not be correlated with the number of lesions/cell but appeared to be related to the C9 to SAC1-8 ratio. With limiting SAC1-8 and excess C9, E were produced from which hemoglobin release could not be prevented by 0.1 M EDTA whereas at lower C9 to SAC1-8 ratios hemoglobin release was prevented by 0.1 M EDTA. These differences most probably reflect functionally different sized transmembrane channels that were produced at different C9 to SAC1-8 ratios.